Pemcord 100/Pemcord 500

Pemetrexed disodium

Treatment of chemotherapy naive patients w/ unresectable malignant pleural mesothelioma. In combination w/ cisplatin as 1st-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology. As monotherapy for the maintenance treatment of locally advanced or metastatic NSCLC other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. As monotherapy for the 2nd-line treatment of locally advanced or metastatic NSCLC other than predominantly squamous cell histology.

In combination w/ cisplatin 500 mg/m² as IV infusion over 10 min on the 1st day of each 21-day cycle. Cisplatin 75 mg/m² infused over 2 hr approx 30 min after completion of the pemetrexed infusion on the 1st day of each 21-day cycle. Patients must receive adequate anti-emetic treatment & appropriate hydration prior to &/or after receiving cisplatin. As single agent Patient treated for NSCLC after prior chemotherapy 500 mg/m² as IV infusion over 10 min on the 1st day of each 21-day cycle.

Hypersensitivity. Concomitant yellow fever vaccine. Lactation.

May suppress bone marrow function. Myelosuppression. Instruct patients to take folic acid & vit B₁₂ as a prophylactic measure to reduce treatment-related toxicity. Skin reactions. Patients w/ mild to moderate renal insufficiency (CrCl 45-79 mL/min) should avoid taking NSAIDs eg, ibuprofen & aspirin (>1.3 g daily) for 2 days before, on the day of, & 2 days following pemetrexed administration. In patients w/ mild to moderate renal insufficiency eligible for pemetrexed therapy NSAIDs w/ long elimination t_½ should be interrupted for at least 5 days prior to, on the day of, & at least 2 days following pemetrexed administration. Dehydration or preexisting HTN or diabetes. Patients should receive adequate antiemetic treatment & appropriate hydration prior to &/or after receiving treatment. Preexisting CV risk factors. Concomitant w/ live attenuated vaccines is not recommended. Radiation pneumonitis in patients treated w/ radiation either prior, during or subsequent to their therapy. Patients on a controlled Na diet. May affect ability to drive or operate machinery. Sexually mature males are advised not to father a child during the treatment & up to 6 mth thereafter. Women of childbearing potential must use effective contraception during treatment. Do not use during pregnancy.

Decreased neutrophils/granulocytes, leukocytes, Hb, platelets; neuropathy-sensory; diarrhoea, vomiting, stomatitis/pharyngitis, nausea, anorexia, constipation; rash, alopecia; creatinine elevation, decreased CrCl; fatigue. Dehydration; taste disturbance; conjunctivitis; dyspepsia.

Potential delayed clearance w/ nephrotoxic drugs (eg, aminoglycoside, loop diuretics, platinum compd, cyclosporin) & drugs that are also tubularly secreted (eg, probenecid, penicillin). May decrease elimination & increase the occurrence of adverse events w/ high dose of NSAIDs (eg, ibuprofen >1,600 mg/day) & aspirin at higher dose (≥1.3 g daily) & NSAIDs having longer t_½ eg, piroxicam or rofecoxib. Possibility of interaction w/ oral anticoagulant. Risk of fatal generalised vaccinale disease w/ Yellow fever vaccine. Risk of systemic, fatal, disease w/ live attenuated vaccines.

Cytotoxic Chemotherapy

L01BA04 - pemetrexed ; Belongs to the class of antimetabolites, folic acid analogues. Used in the treatment of cancer.

Rx